Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To assess safety, tolerance and PK profile of different doses(50mg,100mg,200mg,300mg, 400mg,
500mg,QD)of Icaritin in advanced breast cancer Patients in China